Cellectar Biosciences Inc (CLRB)

[Crusader]

Still lining their FDA ducks up:

Cellectar Biosciences Gets Orphan Drug Designation for Lymphona Treatment
BY Dow Jones & Company, Inc.
— 8:46 AM ET 01/06/2020
Cellectar Biosciences Inc. (CLRB) said Monday the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131 in lymphoplasmacytic lymphoma.
The company said CLR 131 is its lead Phospholipid Drug Conjugate product candidate currently in a Phase 2 clinical study in relapsed or refractory select B-cell lymphomas, including lymphoplasmacytic lymphoma.
Cellectar said CLR 131 has previously been granted Orphan Drug designation for the treatment of multiple myeloma by both the U.S. and the European Commission and Rare Pediatric Disease and Orphan Drug designations for the treatments of neuroblastoma, rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma.
Cellectar shares were up 9% to $2.50 premarket.